Formulation of oryzalin (ORZ) liposomes: In vitro studies and in vivo fate

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 2, 2012, Pages 281-290

  Lopes, Rui M ^a   Corvo, M Luísa ^a   Eleutério, Carla V ^a   Carvalheiro, Manuela C ^a   Scoulica, Effie ^b   Cruz, M Eugénia M ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Dinitroanilines; Leishmaniasis; Liposomes; Nanomedicines; Oryzalin

Indexed keywords

ANTILEISHMANIAL AGENT; LIPOSOME; ORYZALIN; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LEISHMANIASIS; LIVER; LUNG; MALE; MONOCYTE; MOUSE; NONHUMAN; SPLEEN; SUSPENSION;

ANIMALS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DINITROBENZENES; DRUG CARRIERS; DRUG STABILITY; HUMANS; LEISHMANIASIS; LIPOSOMES; MALE; MICE; MONOCYTES; SOLUBILITY; SULFANILAMIDES; SUSPENSIONS; WATER;

EID: 84867877363     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.06.013     Document Type: Article

References (51)

1. P. Desjeux The increase in risk factors for leishmaniasis worldwide Trans. Roy. Soc. Trop. Med. Hyg. 95 2001 239 243 (Pubitemid 33713068)
2. F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R.W. Peeling, J. Alvar, and M. Boelaert Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5 2007 873 882 (Pubitemid 47578388)
3. C.V. David, and N. Craft Cutaneous and mucocutaneous leishmaniasis Dermatol. Ther. 22 2009 491 502
4. J.C. Dujardin Spread of vector-borne diseases and neglect of leishmaniasis, Europe Emerg. Infect. Dis. 14 2008 1013 1018
5. P. Desjeux, and J. Alvar Leishmania/HIV co-infections: epidemiology in Europe Ann. Trop. Med. Parasitol. 97 Suppl. 1 2003 3 15
6. J. Alvar, P. Aparicio, A. Aseffa, M. Den Boer, C. Cañavate, J.-P. Dedet, L. Grandoni, R.T. Horst, R. Lopez-Velez, and J. Moreno The relationship between leishmaniasis and AIDS: the second 10 years Clin. Microbiol. Rev. 21 2008 334 359 (Pubitemid 351555511)
7. L. Monzote Current treatment of Leishmaniasis: a review Antimicrob. Agents J. 2009 9 19
8. N.S. Morrissette, A. Mitra, D. Sept, and L.D. Sibley Dinitroanilines bind alpha-tubulin to disrupt microtubules Mol. Biol. Cell. 15 2004 1960 1968 (Pubitemid 38401842)
9. Y.M. Traub-Cseko, J.M. Ramalho-Ortigão, P. Dantas, S.L. de Castro, H.S. Barbosa, and K.H. Downing Dinitroaniline herbicides against protozoan parasites: the case of Trypanosomacruzi Trends Parasitol. 17 2001 136 141 (Pubitemid 32422182)
10. A. Armson, S.W. Kamau, F. Grimm, J.A. Reynoldson, W.M. Best, L.M. MacDonald, and R.C.A. Thompson A comparison of the effects of a benzimidazole and the dinitroanilines against Leishmania infantum Acta Trop. 73 1999 303 311 (Pubitemid 29528121)
11. T.J. Stokkermans, J.D. Schwartzman, K. Keenan, N.S. Morrissette, L.G. Tilney, and D.S. Roos Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides Exp. Parasitol. 84 1996 355 370 (Pubitemid 26412997)
12. B.J. Fennell, J.A. Naughton, E. Dempsey, and A. Bell Cellular and molecular actions of dinitroaniline and phosphorothioamidate herbicides on Plasmodium falciparum: tubulin as a specific antimalarial target Mol. Biochem. Parasitol. 145 2006 226 238 (Pubitemid 43083364)
13. G. Bhattacharya, M.M. Salem, and K.A. Werbovetz Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin Bioorg. Med. Chem. Lett. 12 2002 2395 2398 (Pubitemid 34879874)
14. M.M. Chan, and D. Fong Inhibition of leishmanias but not host macrophages by the antitubulin herbicide trifluralin Science 249 1990 924 926
15. C. Kelly, C. Jefferies, and S.-A. Cryan Targeted liposomal drug delivery to monocytes and macrophages J. Drug Deliv. 2011 1 11
16. M.M. Gaspar, A. Cruz, A.F. Penha, J. Reymão, A.C. Sousa, C.V. Eleutério, S.A. Domingues, A.G. Fraga, A. Longatto Filho, M.E.M. Cruz, and J. Pedrosa Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis Int. J. Antimicrob. Agents 31 2008 37 45 (Pubitemid 350245738)
17. C.D. Black, G.J. Watson, and R.J. Ward The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis Trans. Roy. Soc. Trop. Med. Hyg. 71 1977 550 552
18. D.A. Schettini, A.P. Costa Val, L.F. Souza, C. Demicheli, O.G.F. Rocha, M.N. Melo, M.S.M. Michalick, and F. Frézard Distribution of liposome-encapsulated antimony in dogs Braz. J. Med. Biol. Res. 36 2003 269 272 (Pubitemid 36285071)
19. G. Carneiro, D.C.M. Santos, M.C. Oliveira, A.P. Fernandes, L.S. Ferreira, G.A. Ramaldes, E.A. Nunan, and L.A. Ferreira Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis J. Liposome Res. 20 1 2010 16 23
20. A. Papagiannaros, C. Bories, C. Demetzos, and P.M. Loiseau Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations Biomed. Pharmacother. 59 2005 545 550 (Pubitemid 41820384)
21. E. Cauchetier, M. Paul, D. Rivollet, H. Fessi, A. Astier, and M. Deniau Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis Int. J. Parasit. 30 2000 777 783 (Pubitemid 30336458)
22. S. Lala, S. Pramanick, S. Mukhopadhyay, S. Bandyopadhyay, and M.K. Basu Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems J. Drug Target. 12 2004 165 175 (Pubitemid 38868164)
23. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 7 2008 2405 2425
24. V. Yardley, and S. Croft A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis Int. J. Antimicrob. Agents 13 2000 243 248 (Pubitemid 30072740)
25. A.K. Cruz, J.S. de Toledo, M. Falade, M.C. Terrão, S. Kamchonwongpaisan, D.E. Kyle, and C. Uthaipibull Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review Curr. Drug Targets 10 3 2009 178 192
26. S.L. Croft, and P. Olliaro Leishmaniasis chemotherapy - challenges and opportunities Clin. Microbiol. Infect. 17 10 2011 1478 1483
27. P. Roy, S. Das, R.G. Auddy, and A. Mukherjee Biological targeting and drug delivery in control of Leishmaniasis J. Cell Anim. Biol. 6 6 2012 78 87
28. C. Marques, M. Carvalheiro, M.a. Pereira, J. Jorge, M.E.M. Cruz, and G.M. Santos-Gomes Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis Vet. J. 178 2008 133 137
29. M. Carvalheiro, J. Jorge, C. Eleutério, A.F. Pinhal, A.C. Sousa, J.G. Morais, and M.E.M. Cruz Trifluralin liposomal formulations active against Leishmania donovani infections Eur. J. Pharm. Biopharm. 71 2009 292 296
30. M.M. Gaspar, S. Neves, F. Portaels, J. Pedrosa, M.T. Silva, and M.E. Cruz Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection Antimicrob. Agents Chemother. 44 2000 2424 2430 (Pubitemid 30650890)
31. M.L. Corvo, O.C. Boerman, W.J. Oyen, J.C. Jorge, M.E. Cruz, D.J. Crommelin, and G. Storm Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model Pharm. Res. 17 2000 600 606 (Pubitemid 30416399)
32. G. Rouser, S. Fkeischer, and A. Yamamoto Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots Lipids 5 1970 494 496
33. M.A. Esteves, I. Fragiadaki, R. Lopes, E. Scoulica, and M.E.M. Cruz Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents Bioorg. Med. Chem. 18 2010 274 281
34. ToxNet, Toxicology Data Network. < http://toxnet.nlm.nih.gov/cgi-bin/ sis/search/a?dbs+hsdb:@term+@DOCNO+6858 > (accessed 01.07.11).
35. W.W. Sułkowski, D. Pentak, K. Nowak, and A. Sułkowska The influence of temperature, cholesterol content and pH on liposome stability J. Mol. Struct. 744 2005 737 747 (Pubitemid 40717435)
36. T. Söderlund, J.Y. Lehtonen, and P.K. Kinnunen Interactions of cyclosporin A with phospholipid membranes: effect of cholesterol Mol. Pharmacol. 55 1 1999 32 38 (Pubitemid 29042519)
37. U. Bhardwaj, and D.J. Burgess Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone Int. J. Pharm. 388 2010 181 189
38. V.-A. Tsotas, S. Mourtas, and S.G. Antimisiaris Dexamethasone incorporating liposomes: effect of lipid composition on drug trapping efficiency and vesicle stability Drug Deliv. 14 2007 441 445 (Pubitemid 350125733)
39. R. Lopes, C.V. Eleutério, L.M.D. Gonçalves, M.E.M. Cruz, and A.J. Almeida Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis Eur. J. Pharm. Sci. 45 4 2012 442 450
40. K.N. Becker, In Vitro Stability and Pharmacokinetics of Novel Antileishmanial Compounds, A Senior Honors Thesis, Ohio State University, 2007. < https://kb.osu.edu/dspace/bitstream/handle/1811/25192/Becker-Honors-Thesis- 052107pdf.pdf?sequence=1 > (accessed 01.07.11).
41. C.-C. Chang, D.-Z. Liu, S.-Y. Lin, H.-J. Liang, W.-C. Hou, W.-J. Huang, C.-H. Chang, F.-M. Ho, and Y.-C. Liang Liposome encapsulation reduces cantharidin toxicity Food Chem. Toxicol. 46 2008 3116 3121
42. L.D. Mayer, M.B. Bally, H. Loughrey, D. Masin, and P.R. Cullis Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors Cancer Res. 50 1990 575 579 (Pubitemid 20054181)
43. P. Deol, and G.K. Khuller Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice Biochim. Biophys. Acta 1334 1997 161 172 (Pubitemid 27117518)
44. R.T. Mehta, R.L. Hopfer, T. McQueen, R.L. Juliano, and G. Lopez-Berestein Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections Antimicrob. Agents Chemother. 31 1987 1901 1903 (Pubitemid 18009558)
45. M.V. Zhukova, O.V. Romanenko, V.A. Nikolaevich, and M.A. Kisel Hemolytic proprieties of miltefosine in liposomes of various lipid compositions Pharm. Chem. J. 44 2010 507 509
46. M. Larabi, V. Yardley, P.M. Loiseau, M. Appel, P. Legrand, and A. Gulik Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B Antimicrob. Agents Chemother. 47 2003 3774 3779 (Pubitemid 37484987)
47. K. Dvorakova, R.T. Dorr, A. Gallegos, T. McClure, and G. Powis Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice J. Chromatogr. B 696 1997 275 281 (Pubitemid 27387453)
48. A. Zaidenberg, C. Marra, S. Villagra, and R. Rule Pharmacokinetics of trifluralin in blood and heart tissue of mice Chemotherapy 55 2009 327 334
49. J. Kamps, and G. Scherphof Receptor versus non-receptor mediated clearance of liposomes Adv. Drug Deliv. Rev. 32 1998 81 97 (Pubitemid 28277177)
50. F.U. Erkorg, and R.E. Menzer Metabolism of trifluralin in rats J. Agric. Food Chem. 33 1985 1061 1070
51. J. Emmerson, and R.C. Anderson Metabolism of trifluralin in the rat and dog Toxicol. Appl. Pharmacol. 9 1966 84 97